An interventional study of Aerobic Exercise Training in Type 2 Diabetes Mellitus, sponsored by Baltimore VA Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by Baltimore VA Medical Center · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,631st largest by planned enrollment of the 2,961 interventional ones that give a count, is one of 152 that started in 2011, is one of 1,242 with no phase, reaches primary completion later than 3 of the 477 other live ones, and was the 982nd registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Montefiore Medical Center · Sites in United States
Ages 18–85
Pfizer · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,308 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 425 · Phase 2 465 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 152 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 2,961 interventional studies, 128 across the 336 observational. Of the 2,651 that completed or were terminated, 1,166 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,489 of 3,308 have an industry lead sponsor. The 10 most frequent:
Baltimore VA Medical Center is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Baltimore VA Medical Center has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
189 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 189 to your calendar (.ics) → With an account.
Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The discovery of the role of endothelial progenitor cells (EPCs) and their involvement in the cardiovascular complications of type 2 diabetes (T2DM) would quickly have a significant impact on the millions of Americans who have T2DM. This project is designed to 1) determine the mechanisms underlying EPC dysfunction in older, sedentary adults with T2DM compared those with normal glucose metabolism and impaired glucose metabolism, and 2) determine if aerobic exercise training is an efficacious therapy for EPC dysfunction in T2DM, and whether improvement in EPC number and function translates to improved endothelial function, increased capillarization, and improved glucose metabolism in T2DM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Type 2 Diabetes Mellitus
Other: Aerobic Exercise Training
Impaired Glucose Tolerance
Other: Aerobic Exercise Training
Normal Glucose Tolerance
Other: Aerobic Exercise Training
6 months of aerobic exercise training, 3 days per week
Endothelial progenitor cell number
Time frame: Baseline
Endothelial progenitor cell number
Time frame: 6-month
Skeletal muscle capillarization
Time frame: Baseline
Skeletal muscle capillarization
Time frame: 6-month
Cardiorespiratory Fitness
Time frame: Baseline
Cardiorespiratory Fitness
Time frame: 6-month
Ran from Jul 2011 to primary completion in Dec 2021, 125 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 125 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Baltimore VA Medical Center